Earnings summaries and quarterly performance for Verona Pharma.
Executive leadership at Verona Pharma.
Research analysts who have asked questions during Verona Pharma earnings calls.
Linda Tsai
Jefferies
5 questions for VRNA
Raghuram Selvaraju
H.C. Wainwright & Co.
5 questions for VRNA
Thomas Shrader
BTIG
5 questions for VRNA
Yasmeen Rahimi
Piper Sandler & Co.
5 questions for VRNA
Boobalan Pachaiyappan
ROTH Capital Partners
4 questions for VRNA
Joon Lee
Truist Securities
3 questions for VRNA
Tiago Fauth
Wells Fargo
3 questions for VRNA
Asim Rana
Truist Securities
2 questions for VRNA
Edward Thomason
Kempen & Co
2 questions for VRNA
Olivia Brayer
Cantor
2 questions for VRNA
Sushila Hernandez
Van Lanschot Kempen Investment Banking
2 questions for VRNA
Tara Bancroft
TD Cowen
2 questions for VRNA
Recent press releases and 8-K filings for VRNA.
- Verona Pharma plc shareholders have approved the proposed acquisition by Merck & Co., Inc..
- The acquisition is valued at $107 per American Depository Share (ADS), representing a total transaction value of approximately $10 billion.
- The transaction is expected to close on October 7, 2025, following the Court Hearing scheduled for October 6, 2025, to sanction the Scheme of Arrangement.
- At the Court Meeting, 99.49% in value of Scheme Shares voted in favor of the resolution to approve the Scheme.
Quarterly earnings call transcripts for Verona Pharma.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more
Let Fintool AI Agent track Verona Pharma's earnings for you
Get instant analysis when filings drop